Daniella Mehalik
Directeur Financier/CFO chez PSYCHEMEDICS CORPORATION
Postes actifs de Daniella Mehalik
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| PSYCHEMEDICS CORPORATION | Directeur Financier/CFO | 27/11/2023 | - |
| Investor Relations Contact | - | - | |
| Treasurer | 27/11/2023 | - |
Historique de carrière de Daniella Mehalik
Anciens postes connus de Daniella Mehalik
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| NEUBASE THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/01/2021 | 01/01/2023 |
| DxTx Medical, Inc. | Comptroller/Controller/Auditor | 01/01/2019 | 01/01/2021 |
Formation de Daniella Mehalik
| Carlow University Of | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
Opérationnelle
| Comptroller/Controller/Auditor | 2 |
| Director of Finance/CFO | 1 |
| Investor Relations Contact | 1 |
Sectorielle
| Health Services | 2 |
| Consumer Services | 2 |
| Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| PSYCHEMEDICS CORPORATION | Health Services |
| Entreprise privées | 2 |
|---|---|
NeuBase Therapeutics, Inc.
 NeuBase Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA. | Health Technology |
| DxTx Medical, Inc. |
- Bourse
- Insiders
- Daniella Mehalik
- Expérience